Patent intelligence · US
US 9914722
Compounds for treating spinal muscular atrophy
Compounds for treating spinal muscular atrophy
Patent details — US 9914722
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 13, 2018
- Expiration
- Mar 8, 2038
- Applicant
- PTC THERAPEUTICS, INC.
- Claims
- 5
- CPC classes
- A61K, A61K31/352, A61P, A61P21/00
Quick answer
US 9914722 (Compounds for treating spinal muscular atrophy) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Mar 13, 2018. Expires Mar 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/352, A61P, A61P21/00, A61P21/04, A61P25/00
More from PTC THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12384789
Compounds for treating Huntington's disease
granted -
US 12384797
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted
Frequently asked questions
What is US patent 9914722?
US 9914722 (Compounds for treating spinal muscular atrophy) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Mar 13, 2018. Expires Mar 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9914722?
PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.
When does US 9914722 expire?
Our index shows an expiration date of Mar 8, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.